Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
VAL401: A NOVEL CANCER THERAPEUTIC COMPOSITION KEY FEATURES VAL401 comprises a novel cancer therapeutic that combines Risperidone with Rumenic Acid as part of a non-toxic lipid formulation in a gelatin capsules that is administered orally being developed by ValiSeek Limited Risperidone is safe and tolerable Efficacy against various cancers Simple and low cost manufacturing Patent protected formulation PROVEN RESULTS VAL401 reduces cellular activity for multiple different cancer cells lines Preclinical efficacy demonstrated in lung, prostate and pancreatic adenocarcinoma models, showing reduced tumour growth rates and survival advantage Dose of Risperidone is within the range licensed as safe and tolerable for CNS use INTELLECTUAL PROPERTY Issued US patents: US 9072743 and US 9375433 with further US and international patent applications pending INITIAL TARGET – NON SMALL CELL LUNG CANCER Phase 2 clinical study underway completion due 2017 MARKET Non Small Cell Lung Cancer accounts for 80% of all lung cancer The market was USD 5.1 billion in 2013, projected to increase to USD7.9 billion in 2020 at a CAGR of 6.6% Suzanne Dilly, ValiSeek Limited CEO [email protected] +44 7736270615